Lilly Gets FDA Label Update for Alzheimer’s Drug To Mitigate Safety Concerns

The FDA will allow a new dosing schedule for Eli Lilly’s Alzheimer’s drug Kisunla that could lessen a known side effect of the monoclonal antibody drug class that has led to several deaths.